- Home
- RDCM vs DRUG Comparison
RDCM vs DRUG Comparison
Compare RDCM & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDCM
- DRUG
- Stock Information
- Founded
- RDCM 1985
- DRUG 2019
- Country
- RDCM Israel
- DRUG United States
- Employees
- RDCM N/A
- DRUG N/A
- Industry
- RDCM Computer peripheral equipment
- DRUG Pharmaceuticals and Biotechnology
- Sector
- RDCM Technology
- DRUG Health Care
- Exchange
- RDCM Nasdaq
- DRUG Nasdaq
- Market Cap
- RDCM 203.7M
- DRUG 199.7M
- IPO Year
- RDCM 1997
- DRUG N/A
- Fundamental
- Price
- RDCM $13.72
- DRUG $42.24
- Analyst Decision
- RDCM Strong Buy
- DRUG Strong Buy
- Analyst Count
- RDCM 1
- DRUG 8
- Target Price
- RDCM $18.00
- DRUG $83.60
- AVG Volume (30 Days)
- RDCM 67.7K
- DRUG 70.3K
- Earning Date
- RDCM 08-13-2025
- DRUG 08-11-2025
- Dividend Yield
- RDCM N/A
- DRUG N/A
- EPS Growth
- RDCM 79.61
- DRUG N/A
- EPS
- RDCM 0.56
- DRUG N/A
- Revenue
- RDCM $66,334,000.00
- DRUG N/A
- Revenue This Year
- RDCM $18.07
- DRUG N/A
- Revenue Next Year
- RDCM $11.52
- DRUG N/A
- P/E Ratio
- RDCM $24.55
- DRUG N/A
- Revenue Growth
- RDCM 18.18
- DRUG N/A
- 52 Week Low
- RDCM $9.23
- DRUG $0.94
- 52 Week High
- RDCM $15.98
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- RDCM 56.64
- DRUG 56.03
- Support Level
- RDCM $12.89
- DRUG $38.00
- Resistance Level
- RDCM $13.50
- DRUG $46.44
- Average True Range (ATR)
- RDCM 0.47
- DRUG 3.19
- MACD
- RDCM 0.06
- DRUG -0.47
- Stochastic Oscillator
- RDCM 89.11
- DRUG 50.24
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.